# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence
Chief Operating Officer to Present Key Advances at Peptide Therapeutics SummitNEW YORK, NY / ACCESSWIRE / April 17, 2024 / Prot...
Protagenic Therapeutics (NASDAQ:PTIX) reported quarterly losses of $(0.38) per share. This is a 171.43 percent decrease over lo...